NOV 15, 2020 8:15 AM PST

Antidepressant May Prevent Worsening of COVID-19 Infections

WRITTEN BY: Annie Lennon

 

Researchers from the Washington University School of Medicine in St. Louis have found that fluvoxamine, a common antidepressant used to treat Obsessive-Compulsive Disorder (OCD), may prevent the degradation of COVID-19 cases in those who have recently been infected. 

The researchers were inspired to conduct the study following findings from last year that fluvoxamine is able to prevent a deadly immune response called sepsis. As negative outcomes from COVID-19 seem to occur from an overproduction of immune cells known as cytokines, the researchers thought that the drug might also be able to treat those infected with the virus. 

As such, they launched a randomized, double-blind trial to investigate the effects of fluvoxamine alongside a placebo in 152 adult outpatients infected with COVID-19. In doing so, they found that none of the participants on fluvoxamine saw clinical deterioration within 15 days, whereas six patients on the placebo did. Of these six people, four were hospitalized for between four and 21 days, with one being put on a ventilator for ten days. 

“The patients who took fluvoxamine did not develop serious breathing difficulties or require hospitalization for problems with lung function,” says Eric J. Lenze, MD, one of the researchers behind the study. 

“Most investigational treatments for COVID-19 have been aimed at the very sickest patients, but it’s also important to find therapies that prevent patients from getting sick enough to require supplemental oxygen or to have to go to the hospital. Our study suggests fluvoxamine may help fill that niche.”

The researchers say that while there are multiple ways in which the drug may have helped patients infected with COVID-19, they suspect it chiefly works by interacting with the sigma-1 receptor to reduce the production of inflammatory molecules. This would match previous research showing that fluvoxamine reduces inflammation in animals with sepsis. 

While interesting results, the researchers warn that there are some limitations to their findings. In particular, they say that their study sample size was small. As such, they now aim to launch a larger trial to test the drug in the coming weeks. 

 

Sources: Neuroscience NewsJAMA Network

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 19, 2020
Drug Discovery & Development
Novel Drug Delivery System for Neurological Diseases
SEP 19, 2020
Novel Drug Delivery System for Neurological Diseases
Scientists at Rutgers have developed a smart drug delivery system that targets inflammation in damaged nerves and helps ...
OCT 02, 2020
Immunology
Stop the Clot: A New Antibody Treatment for Thrombosis
OCT 02, 2020
Stop the Clot: A New Antibody Treatment for Thrombosis
Blood clotting helps stem the bleeding from a wound, suppressing blood loss and stopping pathogenic microorganisms from ...
OCT 13, 2020
Drug Discovery & Development
Uses of Tandem Mass Spectrometry (TMS)
OCT 13, 2020
Uses of Tandem Mass Spectrometry (TMS)
What is tandem mass spectrometry? A powerful analytical tool that is capable of characterizing complex mixtures in drug ...
OCT 29, 2020
Drug Discovery & Development
Scientists Create Antibiotic from Komodo Dragon Blood
OCT 29, 2020
Scientists Create Antibiotic from Komodo Dragon Blood
Researchers from George Mason University in Washington DC have created a synthetic molecule from Komodo Dragon blood tha ...
NOV 01, 2020
Cannabis Sciences
Can Cannabis Treat ALS?
NOV 01, 2020
Can Cannabis Treat ALS?
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative illness that damages motor neurons and leads to progressive m ...
NOV 08, 2020
Neuroscience
Psychedelic DMT Improves Memory by Neurogenesis
NOV 08, 2020
Psychedelic DMT Improves Memory by Neurogenesis
Researchers from the Complutense University of Madrid in Spain have found that dimethyltryptamine (DMT), the psychoactiv ...
Loading Comments...